Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best long term growth stocks to buy according to billionaires.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...